09:07 AM EDT, 10/24/2024 (MT Newswires) -- Merck ( MRK ) said Thursday its anti-PD-1 therapy Keytruda has received two new indications in gynecologic cancers from the European Commission.

The approvals are for Keytruda in combination with carboplatin and paclitaxel, and in combination with chemoradiotherapy, the company said.

The first approval is for the first-line treatment of primary advanced or recurrent endometrial carcinoma, while the second one is for the treatment of a certain locally advanced cervical cancer, Merck ( MRK ) said.

The company said the new indications bring the total number of Keytruda's indications in the EU to 30.

Price: 106.66, Change: +0.28, Percent Change: +0.26